Sonus Pharmaceuticals Announces Fourth Quarter and Year End Results Conference Call and Presentation At WBBA Invest Northwest


BOTHELL, Wash., Feb. 20, 2008 (PRIME NEWSWIRE) -- Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS), an oncology drug development company, today announced that it will release financial results for the fourth quarter of fiscal 2007 ended December 31, 2007, on March 5, 2008 at 1:30 P.M. PT/4:30 P.M. ET.

Michael Martino, President and CEO, will host the call. Individuals wishing to participate in the conference call should dial 800-240-4186 or 303-262-2138 for international calls. An audio replay will be available from March 5, 4:30 P.M. PT/7:30 P.M. ET, for one week at 800-405-2236 or 303-590-3000 for international calls; Conference ID: 11109351.

Additionally, the company announced that Michael Martino, President and CEO, will present at the Washington Biotechnology and Biomedical Association (WBBA) Invest Northwest conference on Tuesday, March 18, 11:50 A.M. PT. The conference is being held in Seattle March 18-19. The Company's presentation will be broadcast live at http://ir.sonuspharma.com/events.cfm. An archive of the call will be available through the same link.

About Sonus Pharmaceuticals

Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and ease of use. Sonus moved an oncology product candidate, SN2310, into a Phase 1 clinical trial in September 2006. For additional information on Sonus, including past news releases, please visit www.sonuspharma.com.


            

Contact Data